Comparison
GHRP-2 vs Ipamorelin
Side-by-side of GHRP-2 and Ipamorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
GHRP-2
GHRP-2 peptide (pralmorelin, KP-102) is a synthetic hexapeptide ghrelin-receptor agonist that triggers pulsatile growth hormone release via the pituitary.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
Effects at a glance
GHRP-2
- •Hexapeptide ghrelin-receptor agonist that stimulates pulsatile GH release within 15 to 30 minutes
- •Strongest appetite signal among GHRPs at standard doses; centrally mediated via NPY/AgRP
- •Produces measurable cortisol and prolactin rise (more than ipamorelin, less than GHRP-6)
- •Approved in Japan as pralmorelin for GH-deficiency diagnostic provocation; not FDA approved
- •Anecdotal protocols use 100 to 300 mcg subcutaneously 2 to 3 times daily on an empty stomach
- •Banned by WADA under S2; detection methods validated in accredited labs
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
Side-by-side
| Attribute | GHRP-2 | Ipamorelin |
|---|---|---|
| Category | peptide | peptide |
| Also known as | Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102, GPA-748 | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 0.5 | 2 |
| Typical dose (mg) ↗ | 0.1 | 0.2 |
| Dosing frequency | 2-3x daily | 2-3x daily |
| Routes | subcutaneous, intranasal, intravenous | subcutaneous, intravenous |
| Onset (hr) | 0.25 | 0.25 |
| Peak (hr) | 0.5 | 1 |
| Molecular weight | 817.97 | 711.86 |
| Molecular formula | C45H55N9O6 | C38H49N9O5 |
| Mechanism | Hexapeptide agonist of the growth-hormone secretagogue receptor (GHS-R1a). Suppresses hypothalamic somatostatin tone and stimulates pituitary somatotrophs, producing a pulsatile GH release with secondary cortisol, prolactin, and ACTH elevation. | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. |
| Legal status | Not FDA approved; approved in Japan as pralmorelin (diagnostic); research-use-only grey market in US/EU; banned by WADA | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled in US (research chemical); approved diagnostic in Japan | Not scheduled (research chemical) |
| Pregnancy | Insufficient data; not recommended | Insufficient data; not recommended |
| CAS | 158861-67-7 | 170851-70-4 |
| PubChem CID | 9919072 | 11338566 |
| Wikidata | Q7235681 | Q1666741 |
Safety profile
GHRP-2
Common side effects
- acute hunger
- head pressure or flushing
- water retention
- vivid dreams
- tingling at injection site
- transient lethargy
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- severe insulin resistance
Interactions
- CJC-1295: synergistic GH release; commonly co-administered for larger pulse(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response and amplify cortisol load(moderate)
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
Which Should You Take?
GHRP-2 and Ipamorelin score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is appetite regulation, pick GHRP-2.
- → If your priority is body composition, pick Ipamorelin.
- → If your priority is growth-hormone axis, pick GHRP-2.
Edge case: Half-lives differ materially (GHRP-2 ~0.5 hr vs Ipamorelin ~2 hr). Ipamorelin reaches steady state faster; GHRP-2 is easier to dial in if tolerability is uncertain.
Default choice: either is defensible. GHRP-2 edges out on goal breadth + legal accessibility; Ipamorelin is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between GHRP-2 and Ipamorelin?
GHRP-2 and Ipamorelin differ in category (peptide vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, GHRP-2 or Ipamorelin?
GHRP-2 half-life is 0.5 hours; Ipamorelin half-life is 2 hours.
Can you stack GHRP-2 with Ipamorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper